Key Takeaways

• California IV hydration is the practice of medicine, whether the operation is brick-and-mortar or mobile, cash-pay or membership-model, or marketed as “wellness,” “recovery,” or “longevity.” An LLC cannot render medical services under Cal. Corp. Code § 17701.04(e).
• RN ownership of the clinical entity is not lawful. RNs can own MSOs under Cal. Corp. Code § 13401.5(a); they cannot own California medical corporations.
• Remediation typically requires forming a physician-owned professional corporation, transferring clinical assets, recasting the existing entity as a Management Services Organization, drafting a compliant MSA, and rebuilding the good-faith exam workflow and standardized procedures.
• IV-specific complications include physician-partner sourcing (often easier than for hyperbaric but harder than for general primary care), sterile-compounding sourcing (USP 797 and any 503A / 503B pharmacy relationships), mobile-operation safety infrastructure, and marketing exposure around outcome claims.
• Historical exposure runs through B&P § 17200, § 17500 false advertising, potential Medical Board discipline for paper medical directors under B&P § 2264, and Board of Registered Nursing discipline for RNs who have been administering without a compliant delegation framework.

If you own a California IV hydration business — a brick-and-mortar clinic, a mobile concierge operation, a wellness lounge, a membership-model longevity practice, or a hybrid, and it operates through an LLC, a non-physician corporation, an RN-owned entity, or a structure without a substantive medical director, you are in a category that California regulators are watching more closely in 2026 than in prior years. The Medical Board and the Board of Registered Nursing have sharpened their expectations around good-faith exams and patient-specific orders. The California Attorney General’s June 2026 Carbon Health settlement demonstrated that CPOM enforcement can reach non-licensee owners personally. And IV hydration itself sits in a category where the marketing has consistently said “wellness” and the regulatory posture has consistently said “medical practice.”

Remediation is possible. It is more expensive than doing it right the first time, and it takes longer than owners initially expect. For most non-compliant IV clinics, it is also the right decision compared to continuing to operate through a structure that does not survive regulatory scrutiny.

This post is the IV-specific remediation guide. It sits under the remediation pillar for California treatment businesses generally and covers the IV-specific issues the general pillar does not address.

Why the Wellness Framing Does Not Solve the Problem

The most common misconception among IV clinic owners approaching remediation is that positioning the clinic as “wellness” or “hydration” removes it from the medical framework. It does not.

Three regulatory realities converge:

IV fluids and additives are legend drugs. Every common IV formulation — saline, electrolyte solutions, B-complex vitamins, vitamin C, glutathione, NAD+, magnesium — is a prescription drug. Preparing and administering prescription drugs requires a prescription from a licensed prescriber based on a good-faith prior examination under B&P § 2242.

Venipuncture and IV administration are clinical procedures. Establishing venous access and administering fluids and medications intravenously is a clinical procedure requiring clinical assessment and clinical oversight. It is not a retail service.

CPOM applies functionally, not by marketing label. B&P §§ 2052 and 2400 and the Moscone-Knox Professional Corporation Act reach the practice of medicine as a matter of substance. Wellness marketing does not remove the practice from the analysis.

Non-compliant IV clinic owners often work from misconceptions the seller conveyed or the industry has normalized. The most persistent:

• “The RN can own it as long as we have a medical director.” An RN cannot own a California medical corporation. The medical director model does not substitute for physician ownership of the clinical entity.
• “Mobile is different.” There is no mobile carve-out from CPOM or the GFE requirement.
• “Cash-pay exempts us.” Payor mix is not a CPOM defense.
• “Standing orders cover our whole menu.” The 2026 Medical Board and BRN posture treats standing orders as insufficient. Patient-specific orders based on a good-faith exam are the operational baseline.

The IV-Specific Remediation Path

The general seven-step remediation playbook applies. Six IV-specific considerations warrant additional attention.

1. Physician-partner sourcing. IV-experienced physicians are more accessible than hyperbaric-experienced physicians. Candidates come from emergency medicine, family or internal medicine with wellness or functional-medicine interests, integrative medicine, and (for higher-intensity infusion practices) anesthesiology or pain medicine. What matters is not just the physician’s specialty but the physician’s willingness to serve as a substantive medical director — conducting or supervising GFEs, developing and approving standardized procedures, being immediately available during operations, managing clinical incidents. Owners transitioning from a paper medical director arrangement often have to source a new physician-partner or renegotiate the current physician’s role and compensation to reflect actual clinical involvement.
2. Good-faith exam workflow rebuild. The 2026 California GFE standard, reflected in Medical Board and BRN guidance and in practitioner analysis, is: a licensed prescriber (physician, NP, or PA) conducts the exam in person or by synchronous video; the exam meets the standard of care under B&P § 2242; the exam results in a patient-specific order for the specific treatment plan, not a standing order; and the exam is documented in the patient chart. Most non-compliant IV clinics need a workflow rebuild that goes beyond documentation cleanup — the exam has to actually happen, by an actually-authorized prescriber, before treatment. Well-designed synchronous video encounters can support GFE for mobile and telehealth-forward operations, but questionnaire-only asynchronous evaluations are treated as insufficient for IV therapy.
3. Standardized procedures rebuild. Where RNs administer IV therapy under physician (or NP) delegation, the delegation runs through written standardized procedures under 16 CCR § 1474. The procedures manual has to be specific to the practice — actual formulations, actual equipment, actual staff — and current, signed by the medical director and executing clinicians, and reviewed on a defined cadence. Generic templates do not meet the standard. Remediation typically means rebuilding the manual from the practice’s actual services and current staff.
4. Compounding pharmacy relationships. IV clinics source formulations either through in-house compounding from single-source ingredients, from 503A pharmacies (patient-specific compounding), or from 503B outsourcing facilities (bulk compounding under FDA registration). USP 797 sterile compounding standards apply to any preparation of sterile compounds; in-house compounding requires the practice meet USP 797 standards for facilities, training, and processes. Remediation includes an audit of the target’s compounding relationships and, where the sourcing is defective, transition to compliant sources. Clinics that have been sourcing from unregistered or gray-market suppliers have both an ongoing sourcing defect and a historical exposure.
5. Mobile-operation safety infrastructure. Mobile IV businesses need documented protocols for safe medication transport and storage (temperature control, secure handling), venipuncture in non-clinical environments, emergency response for adverse reactions in a client’s home (anaphylaxis kit, EMS activation protocol, transport arrangements), waste disposal (sharps, biohazard), and staff safety. Non-compliant mobile operations often lack this infrastructure — remediation includes building it. Professional liability insurance also requires attention: standard policies for brick-and-mortar clinics may not cover mobile administration or may require specific endorsements. Tail coverage for pre-remediation mobile operations should be evaluated as part of the historical exposure analysis.
6. Marketing rebuild. Marketing that has represented IV therapy as “immune-boosting,” “hangover cure,” “anti-aging,” “athletic recovery,” or “chronic fatigue resolution” without adequate qualification is a false-advertising exposure category under B&P § 17500 and the Unfair Competition Law. The FDA has publicly cautioned against unsupported claims for IV wellness. Remediation includes a marketing audit and rebuild aligned with the practice’s actual clinical structure and with defensible representations. Historical marketing exposure — content that has been on the site or in advertising for months or years — is a separate analysis and may require decisions about takedowns and corrective disclosures.

Historical Exposure — IV Considerations

Historical exposure for a non-compliantly-operated California IV clinic runs through several channels.

CPOM exposure under B&P §§ 2052 and 2400. Operating a business that renders medical services without a compliant licensed structure is a public offense. Public prosecutors may pursue civil penalties under B&P § 17200. The AG’s 2026 pattern has demonstrated that CPOM enforcement can reach non-licensee owners personally.

False-advertising exposure under B&P § 17500. IV marketing that overstated outcomes, made unsupported wellness claims, or misrepresented the clinical structure of the practice is exposed to false-advertising claims. This category can be pursued by public prosecutors independently of CPOM.

Consumer-protection exposure. Refund demands and individual claims from patients whose treatments were rendered by a business not authorized to render them. For clinics with substantial patient volume over years of operation, the aggregate exposure can be meaningful.

Medical Board discipline for the physician of record. Any physician who served as paper medical director faces potential Medical Board discipline under B&P § 2264 for aiding and abetting the practice of medicine by an unlicensed entity. The physician’s exposure is separate from the owner’s.

BRN discipline for administering RNs. RNs who have been administering IV therapy under defective standardized procedures, without patient-specific orders, or based on inadequate GFEs face potential Board of Registered Nursing discipline. The RN’s exposure is separate from the owner’s and the physician’s and depends on the fact pattern, including whether the RN reasonably relied on the medical director’s authorization framework.

Compounding-related exposure. Practices that have been sourcing formulations from unregistered pharmacies, using expired products, or compounding in-house without USP 797 compliance face additional exposure. Contamination and adverse-reaction incidents in this category have prompted enforcement scrutiny nationally.

Payor recoupment. Limited for predominantly cash-pay practices. More significant for practices that have offered superbill support for commercial insurance reimbursement.

Common IV Remediation Misconceptions

“I’ll just have the RN work under a stronger medical director agreement.” A medical director agreement does not substitute for a physician-owned clinical entity. The clinical services need to be rendered by a physician-owned PC, and the RN — even a highly skilled and experienced RN — has to be operating under a compliant delegation framework, not an independent one.

“I’ll switch to online-only intake through my website.” Questionnaire-only asynchronous intake is treated as insufficient under 2026 California GFE standards for IV therapy. Synchronous video with a licensed prescriber is the operational baseline for telehealth GFE.

“I’ll rebrand the drips so they don’t sound medical.” Rebranding does not change what the treatment actually is. IV administration of legend drugs is the practice of medicine regardless of the menu label.

“I’ll add a medical director and stop billing the LLC directly.” These are two necessary steps but not sufficient. The clinical services have to be rendered by a physician-owned PC. The LLC cannot render medical services regardless of billing arrangement.

“I’ll wait until I can afford full compliance.” The cost of continued non-compliant operation — measured in exposure that accumulates day by day plus the increasing cost of eventual reactive remediation — typically exceeds the cost of voluntary remediation now.

When to Talk to Counsel

As soon as you recognize the structure is not compliant. Not after a Medical Board inquiry, not after a BRN complaint about an injecting RN, not after an AG contact, not after a patient adverse reaction that triggers a complaint. Voluntary remediation is materially stronger than reactive remediation.

Bay Legal, PC represents non-licensee owners of California IV hydration businesses through structural remediation, GFE and standardized procedures rebuild, compounding-sourcing review, mobile-operation infrastructure build (where applicable), marketing audit, and historical exposure analysis. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

I own an IV clinic through an LLC. What is my exposure?

IV hydration is the practice of medicine in California, and an LLC cannot render medical services under Cal. Corp. Code § 17701.04(e). Operating an IV clinic through an LLC is out of compliance with California CPOM. Practical exposure depends on the fact pattern — operating history, marketing, physician-of-record arrangement, whether any regulatory or consumer complaints have surfaced. What you should not do is continue operating non-compliantly while you decide.

I am an RN who owns my IV clinic. Can I stay involved after remediation?

Yes, but on the MSO side, not the clinical side. RNs cannot own California medical corporations. RNs can own MSOs that contract with physician-owned PCs providing IV services, and can continue to work clinically for the PC as an RN administering under a compliant delegation framework. This is the standard structure for RN entrepreneurs in California IV hydration.

How does mobile IV remediation differ from brick-and-mortar remediation?

The structural remediation is the same — form a physician-owned PC, transfer clinical assets, recast the existing entity as an MSO, draft a compliant MSA, rebuild the GFE and standardized procedures workflow. Mobile operations add safety-infrastructure and insurance considerations that brick-and-mortar practices do not face. Emergency response protocols, medication transport and storage, waste disposal, and mobile-endorsement professional liability coverage are all part of the mobile remediation scope.

What about my compounding pharmacy relationships?

IV clinics that source formulations from 503A or 503B pharmacies need to confirm those pharmacies are properly registered and USP 797-compliant. Practices that have been sourcing from unregistered suppliers have both an ongoing sourcing defect and a historical exposure. Remediation includes an audit of the compounding relationships and, where the sourcing is defective, transition to compliant sources.

My medical director says the current structure is compliant. Should I trust that?

A medical director who is telling the owner an LLC-based IV clinic is compliant either (a) does not understand the California CPOM analysis or (b) is not the medical director the owner needs going forward. Cal. Corp. Code § 17701.04(e) is explicit: an LLC cannot render professional services in California, and IV therapy is the practice of medicine. A candid conversation with California-specific counsel is a prerequisite to remediation.

Talk to a California IV Clinic Remediation Attorney

Bay Legal, PC represents non-licensee owners of California IV hydration businesses through structural remediation and historical exposure mitigation. Whether the operation is brick-and-mortar, mobile, membership-model, or a hybrid, if the current structure is not compliant, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.